OXFORD BIOMEDICA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 302.5 GBX | +0.83% |
|
-2.89% | +37.50% |
| 06-25 | ArcticZymes Technologies Nominates New Chair | MT |
| 06-18 | EARNINGS AND TRADING: Cordel thrilled by Middle East contract win | AN |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 495.7 | 847.6 | 1,059 | 426 | 213 | 318.4 | - | - |
| Enterprise Value (EV) 1 | 487.8 | 814.5 | 950.4 | 324.5 | 213 | 300.1 | 303.5 | 274.6 |
| P/E ratio | -29.2 x | -132 x | 55.4 x | -10.7 x | -1.35 x | -8.28 x | -21.5 x | 32.2 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 7.74 x | 9.66 x | 7.42 x | 3.04 x | 2.38 x | 2.46 x | 1.93 x | 1.52 x |
| EV / Revenue | 7.61 x | 9.28 x | 6.66 x | 2.32 x | 2.38 x | 2.32 x | 1.84 x | 1.31 x |
| EV / EBITDA | -93.8 x | 112 x | 26.5 x | 203 x | -4.03 x | -34.5 x | 15.7 x | 5.77 x |
| EV / FCF | -16.7 x | -79.5 x | 59.4 x | -11.2 x | - | -13.8 x | 292 x | 10.8 x |
| FCF Yield | -6% | -1.26% | 1.68% | -8.91% | - | -7.26% | 0.34% | 9.22% |
| Price to Book | - | 7.3 x | 5.48 x | 2.08 x | - | 5.25 x | 8.23 x | 7.95 x |
| Nbr of stocks (in thousands) | 76,848 | 82,294 | 86,126 | 96,263 | 96,804 | 105,269 | - | - |
| Reference price 2 | 6.450 | 10.30 | 12.30 | 4.425 | 2.200 | 3.025 | 3.025 | 3.025 |
| Announcement Date | 06/05/20 | 15/04/21 | 20/04/22 | 25/04/23 | 29/04/24 | - | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 64.06 | 87.73 | 142.8 | 140 | 89.54 | 129.3 | 164.9 | 209.4 |
| EBITDA 1 | -5.2 | 7.3 | 35.9 | 1.6 | -52.8 | -8.699 | 19.29 | 47.59 |
| EBIT 1 | -14.47 | -5.694 | 20.77 | -30.22 | -184.2 | -36.07 | -16.12 | 6.775 |
| Operating Margin | -22.58% | -6.49% | 14.54% | -21.59% | -205.69% | -27.89% | -9.78% | 3.24% |
| Earnings before Tax (EBT) 1 | -20.89 | -6.572 | 19.88 | -45.98 | -188.5 | -40.12 | -17.09 | 6.179 |
| Net income 1 | -16.07 | -6.245 | 19.01 | -39.16 | -157.5 | -36.47 | -12.48 | 11.49 |
| Net margin | -25.08% | -7.12% | 13.31% | -27.97% | -175.89% | -28.2% | -7.57% | 5.49% |
| EPS 2 | -0.2210 | -0.0781 | 0.2220 | -0.4129 | -1.631 | -0.3652 | -0.1407 | 0.0939 |
| Free Cash Flow 1 | -29.28 | -10.24 | 15.99 | -28.91 | - | -21.78 | 1.04 | 25.32 |
| FCF margin | -45.71% | -11.67% | 11.2% | -20.65% | - | -16.84% | 0.63% | 12.09% |
| FCF Conversion (EBITDA) | - | - | 44.55% | - | - | - | 5.39% | 53.21% |
| FCF Conversion (Net income) | - | - | 84.13% | - | - | - | - | 220.46% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 06/05/20 | 15/04/21 | 20/04/22 | 25/04/23 | 29/04/24 | - | - | - |
1GBP in Million2GBP
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 31.96 | 33.98 | 53.75 | 81.25 | 61.54 | 64.03 | 75.96 | 43.06 | 46.48 | 53.3 | 76.7 |
| EBITDA | -3.79 | -0.398 | 7.7 | 27.09 | 8.808 | -5.785 | 7.385 | -33.73 | -19.1 | - | - |
| EBIT 1 | -9.572 | -5.766 | 0.072 | 19.66 | 1.11 | -19.16 | -11.06 | -50.75 | -133.4 | -17.1 | -7.8 |
| Operating Margin | -29.95% | -16.97% | 0.13% | 24.19% | 1.8% | -29.92% | -14.56% | -117.85% | -287.07% | -32.08% | -10.17% |
| Earnings before Tax (EBT) 1 | -8.776 | -6.126 | -0.446 | 19.22 | 0.663 | -27.38 | -18.59 | -52.34 | -136.2 | -18.6 | -9.3 |
| Net income 1 | -5.898 | -6.679 | 0.434 | 18.07 | 0.942 | -25.48 | -13.67 | -47.96 | -152.8 | -18.6 | -4.9 |
| Net margin | -18.45% | -19.66% | 0.81% | 22.24% | 1.53% | -39.8% | -18% | -111.37% | -328.73% | -34.9% | -6.39% |
| EPS 2 | -0.0727 | -0.0869 | 0.008800 | 0.2136 | 0.008400 | -0.2729 | -0.1400 | -0.4974 | -1.134 | -0.1467 | -0.0262 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 06/05/20 | 17/09/20 | 15/04/21 | 22/09/21 | 20/04/22 | 15/09/22 | 25/04/23 | 20/09/23 | 29/04/24 | - | - |
1GBP in Million2GBP
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 7.85 | 33.1 | 109 | 102 | - | 18.3 | 14.9 | 43.8 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -29.3 | -10.2 | 16 | -28.9 | - | -21.8 | 1.04 | 25.3 |
| ROE (net income / shareholders' equity) | - | -6.63% | 12.7% | -20% | - | -60.9% | -38.7% | 8.85% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | -14.5% | -9.92% | -4.8% |
| Assets 1 | - | - | - | - | - | 250.9 | 125.8 | -239.5 |
| Book Value Per Share 2 | - | 1.410 | 2.240 | 2.130 | - | 0.5800 | 0.3700 | 0.3800 |
| Cash Flow per Share 2 | -0.0500 | 0.0400 | 0.3000 | -0.1300 | - | -0.4500 | 0.0600 | 0.0800 |
| Capex 1 | 25.8 | 13.4 | 9.46 | 16.3 | - | 12.9 | 11.7 | 11.3 |
| Capex / Sales | 40.23% | 15.23% | 6.63% | 11.64% | - | 9.96% | 7.09% | 5.41% |
| Announcement Date | 06/05/20 | 15/04/21 | 20/04/22 | 25/04/23 | 29/04/24 | - | - | - |
1GBP in Million2GBP
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
3
GBP
Average target price
4.489
GBP
Spread / Average Target
+49.62%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +37.50% | 399M | |
| +16.13% | 122B | |
| +19.65% | 115B | |
| +21.22% | 26.64B | |
| -23.84% | 19.91B | |
| -17.47% | 16.32B | |
| -45.95% | 15.52B | |
| -19.28% | 15.49B | |
| +63.81% | 14.83B | |
| +1.94% | 13.67B |
- Stock Market
- Equities
- OXB Stock
- Financials Oxford Biomedica plc
